AbbVie has purchased an exclusive right to acquire Mitokinin, which includes its PINK1 clinical program for the potential treatment of Parkinson’s disease. Under this agreement, Mitokinin will receive an upfront payment and continue to develop its PINK1 compounds by completing an investigational new drug (IND) application and enabling…
A grant from the Michael J. Fox Foundation (MJFF) will help Clene Nanomedicine to advance in development CNM-Au8, its cellular energy-promoting, investigational Parkinson’s treatment. The grant will help to support preclinical studies in patients’ nerve cells and mouse models of the disease, as well as facilitate the launch of a Phase 2 safety and effectiveness…
IMAC Holdings has completed dosing the first group of participants in a Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor symptom of Parkinson’s disease. The group consists of five patients who received a…
The impact of deep brain stimulation (DBS) in improving motor function in people with Parkinson’s disease may be related to a patient’s response to levodopa therapy, and to the type of DBS administered, according to a small study. Patients who responded to levodopa demonstrated better…
Scientists have found that berberine, a natural plant compound that has been used in China as an over-the-counter medicine for diarrhea, can promote the production of l-dopa, a precursor of the brain chemical dopamine that is missing in patients with Parkinson’s disease, in the gastrointestinal tracts of mice. The…
People with Parkinson’s disease who failed to take their medication as prescribed — meaning, were nonadherent — showed no difference in measures of health-related quality of life (HRQoL) than those who were fully adherent, a questionnaire study of a patient group found. This finding…
Changes in the composition of fat molecules on the membranes of nerve cells appear to change how the alpha-synuclein protein interacts with these same cell membranes, possibly promoting the aggregation that characterizes Parkinson’s disease, new research reports. The study, “The docking of synaptic vesicles on the presynaptic membrane induced by…
Abnormal blood sugar (glucose) levels, either lower or higher than the norm, appears to be linked with a faster progression of motor difficulties in people with Parkinson’s disease, research suggests. The brief report on this finding, “Euglycemia Indicates Favorable Motor Outcome in Parkinson’s Disease,” was published in the journal…
Newronika‘s AlphaDBS, an innovative deep brain stimulation (DBS) system being evaluated in patients with Parkinson’s disease, has received CE Mark approval in Europe. The CE Mark is a seal of approval issued by the European Commission that means products have been assessed to meet pre-established safety, health,…
Biogen and Sangamo Therapeutics have begun a collaboration to develop and commercialize gene therapies for Parkinson’s and Alzheimer’s diseases, as well as an undisclosed neuromuscular disease. The five-year collaboration will join Sangamo’s science expertise and proprietary technology with Biogen’s clinical development capabilities. The goal is to submit investigational…
Get regular updates to your inbox.
